annual CFF:
-$526.45M-$507.72M(-2711.17%)Summary
- As of today (July 1, 2025), BMRN annual cash flow from financing activities is -$526.45 million, with the most recent change of -$507.72 million (-2711.17%) on December 31, 2024.
- During the last 3 years, BMRN annual CFF has fallen by -$526.40 million (-1096664.58%).
- BMRN annual CFF is now -156.87% below its all-time high of $925.72 million, reached on December 31, 2015.
Performance
BMRN Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
-$38.78M-$41.64M(-1456.38%)Summary
- As of today (July 1, 2025), BMRN quarterly cash flow from financing activities is -$38.78 million, with the most recent change of -$41.64 million (-1456.38%) on March 31, 2025.
- Over the past year, BMRN quarterly CFF has increased by +$4.01 million (+9.38%).
- BMRN quarterly CFF is now -104.24% below its all-time high of $914.79 million, reached on March 31, 2015.
Performance
BMRN quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
-$522.43M+$4.01M(+0.76%)Summary
- As of today (July 1, 2025), BMRN TTM cash flow from financing activities is -$522.43 million, with the most recent change of +$4.01 million (+0.76%) on March 31, 2025.
- Over the past year, BMRN TTM CFF has dropped by -$501.65 million (-2414.36%).
- BMRN TTM CFF is now -154.26% below its all-time high of $962.83 million, reached on June 30, 2015.
Performance
BMRN TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
BMRN Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -2711.2% | +9.4% | -2414.4% |
| 3 y3 years | -10000.0% | -53.4% | -10000.0% |
| 5 y5 years | -605.0% | -97.1% | -195.7% |
BMRN Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | <-9999.0% | at low | -407.5% | +92.2% | -4938.4% | +0.8% |
| 5 y | 5-year | -390.7% | at low | -106.9% | +92.2% | -194.8% | +0.8% |
| alltime | all time | -156.9% | at low | -104.2% | +92.2% | -154.3% | +0.8% |
BMRN Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$38.78M(-1456.4%) | -$522.43M(-0.8%) |
| Dec 2024 | -$526.45M(+2711.2%) | $2.86M(-100.6%) | -$526.45M(+1.5%) |
| Sep 2024 | - | -$499.13M(-4057.5%) | -$518.47M(+2475.7%) |
| Jun 2024 | - | $12.61M(-129.5%) | -$20.13M(-3.1%) |
| Mar 2024 | - | -$42.79M(-494.8%) | -$20.78M(+11.0%) |
| Dec 2023 | -$18.73M(+0.4%) | $10.84M(-1475.6%) | -$18.73M(+0.2%) |
| Sep 2023 | - | -$788.00K(-106.6%) | -$18.70M(+80.3%) |
| Jun 2023 | - | $11.96M(-129.4%) | -$10.37M(-69.6%) |
| Mar 2023 | - | -$40.74M(-474.8%) | -$34.11M(+82.9%) |
| Dec 2022 | -$18.65M(>+9900.0%) | $10.87M(+44.1%) | -$18.65M(+23.3%) |
| Sep 2022 | - | $7.54M(-164.0%) | -$15.12M(-36.2%) |
| Jun 2022 | - | -$11.78M(-53.4%) | -$23.70M(+2358.0%) |
| Mar 2022 | - | -$25.28M(-275.6%) | -$964.00K(+1908.3%) |
| Dec 2021 | -$48.00K(-100.0%) | $14.40M(-1496.3%) | -$48.00K(-100.0%) |
| Sep 2021 | - | -$1.03M(-109.4%) | -$380.60M(+1.1%) |
| Jun 2021 | - | $10.95M(-144.9%) | -$376.31M(-313.3%) |
| Mar 2021 | - | -$24.36M(-93.3%) | $176.43M(-2.6%) |
| Dec 2020 | $181.12M(-342.5%) | -$366.15M(<-9900.0%) | $181.12M(-67.1%) |
| Sep 2020 | - | $3.26M(-99.4%) | $551.32M(+1.0%) |
| Jun 2020 | - | $563.69M(-2965.6%) | $546.08M(-887.3%) |
| Mar 2020 | - | -$19.67M(-586.7%) | -$69.36M(-7.1%) |
| Dec 2019 | -$74.67M(-80.8%) | $4.04M(-304.7%) | -$74.67M(-83.2%) |
| Sep 2019 | - | -$1.98M(-96.2%) | -$445.08M(+1.6%) |
| Jun 2019 | - | -$51.76M(+107.2%) | -$437.95M(+8.6%) |
| Mar 2019 | - | -$24.98M(-93.2%) | -$403.22M(+3.9%) |
| Dec 2018 | -$388.01M(-176.5%) | -$366.36M(-7212.4%) | -$388.01M(+4438.6%) |
| Sep 2018 | - | $5.15M(-130.2%) | -$8.55M(-101.8%) |
| Jun 2018 | - | -$17.03M(+74.4%) | $468.24M(-7.1%) |
| Mar 2018 | - | -$9.77M(-174.6%) | $504.12M(-0.6%) |
| Dec 2017 | $507.14M(-30.3%) | $13.10M(-97.3%) | $507.14M(-1.3%) |
| Sep 2017 | - | $481.94M(+2455.9%) | $513.96M(-33.2%) |
| Jun 2017 | - | $18.86M(-379.6%) | $769.03M(+1.5%) |
| Mar 2017 | - | -$6.74M(-133.9%) | $757.63M(+4.2%) |
| Dec 2016 | $727.11M(-21.5%) | $19.91M(-97.3%) | $727.11M(+1.5%) |
| Sep 2016 | - | $737.00M(+9787.4%) | $716.71M(-4436.6%) |
| Jun 2016 | - | $7.45M(-120.0%) | -$16.53M(-37.2%) |
| Mar 2016 | - | -$37.26M(-491.5%) | -$26.33M(-102.8%) |
| Dec 2015 | $925.72M(+402.6%) | $9.52M(+152.8%) | $925.72M(-3.3%) |
| Sep 2015 | - | $3.77M(-260.1%) | $957.73M(-0.5%) |
| Jun 2015 | - | -$2.35M(-100.3%) | $962.83M(+0.1%) |
| Mar 2015 | - | $914.79M(+2103.1%) | $962.02M(+422.3%) |
| Dec 2014 | $184.20M(-75.3%) | $41.52M(+368.1%) | $184.20M(-78.3%) |
| Sep 2014 | - | $8.87M(-380.8%) | $847.60M(-0.4%) |
| Jun 2014 | - | -$3.16M(-102.3%) | $851.03M(-2.2%) |
| Mar 2014 | - | $136.96M(-80.6%) | $869.81M(+16.5%) |
| Dec 2013 | $746.67M(+139.1%) | $704.93M(+5631.6%) | $746.67M(+818.3%) |
| Sep 2013 | - | $12.30M(-21.3%) | $81.31M(+2.5%) |
| Jun 2013 | - | $15.62M(+13.0%) | $79.31M(-74.6%) |
| Mar 2013 | - | $13.82M(-65.1%) | $312.67M(+0.1%) |
| Dec 2012 | $312.29M(+964.5%) | $39.56M(+283.9%) | $312.29M(+10.3%) |
| Sep 2012 | - | $10.31M(-95.9%) | $283.17M(+0.9%) |
| Jun 2012 | - | $248.97M(+1751.5%) | $280.62M(+609.5%) |
| Mar 2012 | - | $13.45M(+28.7%) | $39.55M(+34.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2011 | $29.34M(+737.3%) | $10.45M(+34.6%) | $29.34M(+232.4%) |
| Sep 2011 | - | $7.76M(-1.8%) | $8.82M(+13.5%) |
| Jun 2011 | - | $7.90M(+144.4%) | $7.78M(-423.6%) |
| Mar 2011 | - | $3.23M(-132.1%) | -$2.40M(-168.6%) |
| Dec 2010 | $3.50M(-105.5%) | -$10.07M(-250.1%) | $3.50M(-76.7%) |
| Sep 2010 | - | $6.71M(-394.7%) | $15.02M(+8.6%) |
| Jun 2010 | - | -$2.28M(-124.9%) | $13.83M(-125.6%) |
| Mar 2010 | - | $9.14M(+531.2%) | -$53.99M(-15.4%) |
| Dec 2009 | -$63.79M(-379.7%) | $1.45M(-73.8%) | -$63.79M(+1.3%) |
| Sep 2009 | - | $5.52M(-107.9%) | -$62.98M(-4.5%) |
| Jun 2009 | - | -$70.10M(>+9900.0%) | -$65.97M(-783.5%) |
| Mar 2009 | - | -$653.00K(-129.0%) | $9.65M(-57.7%) |
| Dec 2008 | $22.81M(-93.0%) | $2.25M(-11.4%) | $22.81M(-4.4%) |
| Sep 2008 | - | $2.54M(-54.0%) | $23.87M(-9.0%) |
| Jun 2008 | - | $5.52M(-55.9%) | $26.24M(-92.2%) |
| Mar 2008 | - | $12.51M(+278.3%) | $337.38M(+3.9%) |
| Dec 2007 | $324.57M(+9.7%) | $3.31M(-32.6%) | $324.57M(+0.7%) |
| Sep 2007 | - | $4.91M(-98.5%) | $322.36M(+0.6%) |
| Jun 2007 | - | $316.67M(<-9900.0%) | $320.44M(-2040.5%) |
| Mar 2007 | - | -$310.00K(-128.3%) | -$16.51M(-105.6%) |
| Dec 2006 | $295.94M(+883.6%) | $1.10M(-63.3%) | $295.94M(+0.2%) |
| Sep 2006 | - | $2.99M(-114.7%) | $295.30M(-15.7%) |
| Jun 2006 | - | -$20.29M(-106.5%) | $350.50M(-1.7%) |
| Mar 2006 | - | $312.14M(>+9900.0%) | $356.73M(+1085.7%) |
| Dec 2005 | $30.09M(-207.9%) | $459.00K(-99.2%) | $30.09M(+84.9%) |
| Sep 2005 | - | $58.19M(-513.7%) | $16.27M(-128.6%) |
| Jun 2005 | - | -$14.07M(-3.0%) | -$56.94M(+34.0%) |
| Mar 2005 | - | -$14.50M(+8.5%) | -$42.50M(+52.4%) |
| Dec 2004 | -$27.89M(-113.1%) | -$13.36M(-11.0%) | -$27.89M(+102.9%) |
| Sep 2004 | - | -$15.01M(-4124.4%) | -$13.75M(-981.3%) |
| Jun 2004 | - | $373.00K(+258.7%) | $1.56M(-98.8%) |
| Mar 2004 | - | $104.00K(-86.8%) | $127.01M(-40.5%) |
| Dec 2003 | $213.47M(+5446.1%) | $785.00K(+163.4%) | $213.47M(-0.5%) |
| Sep 2003 | - | $298.00K(-99.8%) | $214.51M(-0.5%) |
| Jun 2003 | - | $125.82M(+45.3%) | $215.60M(+138.1%) |
| Mar 2003 | - | $86.57M(+4643.3%) | $90.54M(+2252.4%) |
| Dec 2002 | $3.85M(-97.5%) | $1.82M(+31.0%) | $3.85M(-96.5%) |
| Sep 2002 | - | $1.39M(+83.5%) | $108.83M(-0.5%) |
| Jun 2002 | - | $759.00K(-693.0%) | $109.38M(-27.9%) |
| Mar 2002 | - | -$128.00K(-100.1%) | $151.61M(-0.9%) |
| Dec 2001 | $152.99M(+1921.8%) | $106.81M(+5414.2%) | $152.99M(+228.9%) |
| Sep 2001 | - | $1.94M(-95.5%) | $46.51M(-4.7%) |
| Jun 2001 | - | $42.99M(+3342.3%) | $48.82M(+713.3%) |
| Mar 2001 | - | $1.25M(+277.3%) | $6.00M(-20.7%) |
| Dec 2000 | $7.57M(-92.1%) | $331.00K(-92.2%) | $7.57M(+3.3%) |
| Sep 2000 | - | $4.25M(+2342.0%) | $7.33M(-90.1%) |
| Jun 2000 | - | $174.00K(-93.8%) | $73.78M(-25.1%) |
| Mar 2000 | - | $2.81M(+3025.6%) | $98.55M(+3.0%) |
| Dec 1999 | $95.69M(+385.7%) | $90.00K(-99.9%) | $95.69M(+0.1%) |
| Sep 1999 | - | $70.70M(+183.4%) | $95.60M(+283.9%) |
| Jun 1999 | - | $24.94M(<-9900.0%) | $24.90M(<-9900.0%) |
| Mar 1999 | - | -$43.00K | -$43.00K |
| Dec 1998 | $19.70M | - | - |
FAQ
- What is BioMarin Pharmaceutical annual cash flow from financing activities?
- What is the all time high annual CFF for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual CFF year-on-year change?
- What is BioMarin Pharmaceutical quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly CFF year-on-year change?
- What is BioMarin Pharmaceutical TTM cash flow from financing activities?
- What is the all time high TTM CFF for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical TTM CFF year-on-year change?
What is BioMarin Pharmaceutical annual cash flow from financing activities?
The current annual CFF of BMRN is -$526.45M
What is the all time high annual CFF for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual cash flow from financing activities is $925.72M
What is BioMarin Pharmaceutical annual CFF year-on-year change?
Over the past year, BMRN annual cash flow from financing activities has changed by -$507.72M (-2711.17%)
What is BioMarin Pharmaceutical quarterly cash flow from financing activities?
The current quarterly CFF of BMRN is -$38.78M
What is the all time high quarterly CFF for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly cash flow from financing activities is $914.79M
What is BioMarin Pharmaceutical quarterly CFF year-on-year change?
Over the past year, BMRN quarterly cash flow from financing activities has changed by +$4.01M (+9.38%)
What is BioMarin Pharmaceutical TTM cash flow from financing activities?
The current TTM CFF of BMRN is -$522.43M
What is the all time high TTM CFF for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high TTM cash flow from financing activities is $962.83M
What is BioMarin Pharmaceutical TTM CFF year-on-year change?
Over the past year, BMRN TTM cash flow from financing activities has changed by -$501.65M (-2414.36%)